BACK vs. SNES, EVOK, SMFL, MBIO, VRPX, NAVB, GMVDF, MDGS, UTRS, and AEMD
Should you be buying IMAC stock or one of its competitors? The main competitors of IMAC include SenesTech (SNES), Evoke Pharma (EVOK), Smart for Life (SMFL), Mustang Bio (MBIO), Virpax Pharmaceuticals (VRPX), Navidea Biopharmaceuticals (NAVB), G Medical Innovations (GMVDF), Xylo Technologies (MDGS), Minerva Surgical (UTRS), and Aethlon Medical (AEMD). These companies are all part of the "medical" sector.
IMAC (NASDAQ:BACK) and SenesTech (NASDAQ:SNES) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, community ranking, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.
SenesTech has lower revenue, but higher earnings than IMAC.
In the previous week, IMAC had 58 more articles in the media than SenesTech. MarketBeat recorded 58 mentions for IMAC and 0 mentions for SenesTech. IMAC's average media sentiment score of 0.12 beat SenesTech's score of 0.00 indicating that IMAC is being referred to more favorably in the media.
IMAC has a beta of 0.25, indicating that its stock price is 75% less volatile than the S&P 500. Comparatively, SenesTech has a beta of 0.85, indicating that its stock price is 15% less volatile than the S&P 500.
IMAC has a net margin of -176.22% compared to SenesTech's net margin of -646.27%. SenesTech's return on equity of -199.86% beat IMAC's return on equity.
SenesTech received 320 more outperform votes than IMAC when rated by MarketBeat users. Likewise, 65.44% of users gave SenesTech an outperform vote while only 0.00% of users gave IMAC an outperform vote.
5.8% of IMAC shares are owned by institutional investors. Comparatively, 5.2% of SenesTech shares are owned by institutional investors. 10.0% of IMAC shares are owned by company insiders. Comparatively, 5.3% of SenesTech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
SenesTech has a consensus target price of $3.50, indicating a potential upside of 380.44%. Given SenesTech's higher possible upside, analysts clearly believe SenesTech is more favorable than IMAC.
Summary
SenesTech beats IMAC on 9 of the 15 factors compared between the two stocks.
Get IMAC News Delivered to You Automatically
Sign up to receive the latest news and ratings for BACK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BACK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
